{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:16:32Z","timestamp":1790619392102,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.rpth.2026.103375","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:54:00Z","timestamp":1770047640000},"page":"103375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8575-5936","authenticated-orcid":false,"given":"Magdolna","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tain\u00e1","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van Oerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman M.","family":"Hackeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne J.H.","family":"Magdelijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.C.","family":"Henskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ged","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri M.H.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103375_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2026.103375_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.103375_bib3","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103375_bib4","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103375_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.rpth.2026.103375_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.684638","article-title":"Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice","volume":"12","author":"Roberti","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rpth.2026.103375_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12518","article-title":"A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib8","first-page":"2637","article-title":"Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis","volume":"25","author":"Luo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.rpth.2026.103375_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","article-title":"Engineered FXa variants retain procoagulant activity independent of direct FXa inhibitors","volume":"8","author":"Verhoef","year":"2017","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.103375_bib10","first-page":"8","article-title":"OC 24.3: VMX-C001 is an effective factor Xa inhibitor reversal agent and displays a favorable pharmacodynamic profile in animal models","volume":"6","author":"Verhoef","year":"2022","journal-title":"Res Pract Thromb Haemostat"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103375_bib11","first-page":"40","article-title":"Phase 1 study of the safety, tolerability, pharmacokinetics and pharmacodynamics of VMX-C001 in healthy subjects. 2023 ISTH Congress Abstract OC 31.3 [abstract]","volume":"7","author":"Short","year":"2023","journal-title":"Res Pract Throm Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/jth.13300","article-title":"A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma","volume":"14","author":"Letertre","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib15","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1111\/jth.15901","article-title":"Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure","volume":"20","author":"Shaw","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) Recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/1389200218666170417124035","article-title":"Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges","volume":"18","author":"Favaloro","year":"2017","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.rpth.2026.103375_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2141.1994.tb04876.x","article-title":"Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin","volume":"87","author":"Arnout","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103375_bib20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ajh.25606","article-title":"The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)","volume":"94","author":"Favaloro","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.103375_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2020.07.020","article-title":"Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan","volume":"195","author":"Ieko","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103375_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.thromres.2015.02.020","article-title":"Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study","volume":"135","author":"Douxfils","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103375_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2026.103375_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221138297","article-title":"Differential neutralization of apixaban, betrixaban, edoxaban, and rivaroxaban by andexanet alfa as measured by whole blood thromboelastographic analysis","volume":"28","author":"Mehrotra","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.103375_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2026.103375_bib27","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1161\/STROKEAHA.117.017981","article-title":"Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions","volume":"48","author":"Ebner","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2026.103375_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2026.103375_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2026.103375_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42466-021-00105-4","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban","volume":"3","author":"H\u00e4rtig","year":"2021","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.rpth.2026.103375_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/anae.15254","article-title":"A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury","volume":"76","author":"Oberladst\u00e4tter","year":"2021","journal-title":"Anaesthesia"},{"key":"10.1016\/j.rpth.2026.103375_bib32","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1055\/s-0042-1751072","article-title":"Rapid Detection of apixaban by a ROTEM-based approach and reversibility with andexanet alfa or DOAC-Stop","volume":"6","author":"Taune","year":"2022","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2026.103375_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ejh.13050","article-title":"Screening test for direct oral anticoagulants with the dilute Russell viper venom time","volume":"100","author":"Pratt","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.103375_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ijlh.14300","article-title":"Detection of direct oral anticoagulants with the diluted Russel\u2019s viper venom time","volume":"46","author":"Kl\u00f6ter","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2026.103375_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2017.06.034","article-title":"An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants","volume":"157","author":"Sennesael","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103375_bib37","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.3390\/jcm14238274","article-title":"Multicenter evaluation of different anti-Xa assays and diluted russell's viper venom time in ex vivo plasma samples from patients treated with rivaroxaban or apixaban","volume":"14","author":"Bo\u017ei\u010d Mijovski","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.103375_bib38","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103375_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1254\/fpj.22107","article-title":"[Andexanet alfa (ONDEXXYA\u00ae for intravenous injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence.]","volume":"158","author":"Yajima","year":"2023","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.rpth.2026.103375_bib42","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0041-1740180","article-title":"Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban","volume":"122","author":"Benz","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000002910","article-title":"Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors","volume":"131","author":"Grottke","year":"2019","journal-title":"Anesthesiology"},{"key":"10.1016\/j.rpth.2026.103375_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib45","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study","volume":"15","author":"Song","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rth2.12089","article-title":"Pharmacological reversal of the direct oral anticoagulants\u2014A comprehensive review of the literature","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","volume":"21","author":"Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103375_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12633","article-title":"Direct oral anticoagulant removal by a DOAC filter: impact on lupus anticoagulant testing\u2014evaluation on spiked and patient samples","volume":"6","author":"Linskens","year":"2022","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:03:01Z","timestamp":1779451381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2475037926000336"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103375","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103375"}}